Valeant (VRX) Oral Relistor Approval a 'Slight Positive' - RBC Capital

Rodman & Renshaw Reiterates Buy Rating on Valeant (VRX)

Rodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $90. Comments following an FDA panel vote in favor of brodalumab approval.

"On July 19, 2016, an FDA advisory committee gave brodalumab, an investigational anti interleukin-17 (anti-IL-17) monoclonal antibody for moderate-to-severe plaque psoriasis, a unanimous 18-0 vote in favor of approval. The panel also recommended, as we anticipated, a safety... More

Valeant (VRX) Pipeline Developments 'Positive', But In-Line with Expectations - BMO Capital

BMO Capital analyst Gary Nachman weighed in on Valeant Pharmaceuticals (NYSE: VRX) after an FDA advisory panel resulted in unanimous support for the approval of brodalumab for the treatment of moderate to severe plaque psoriasis. However, the majority of the panel (78%) supported additional risk... More

Valeant (VRX) FDA Catalysts a Mixed Bag and Expected, Now Focus on Earnings - Wells Fargo

Wells Fargo analyst David Maris weighed in on Valeant Pharmaceuticals (NYSE: VRX) after a FDA AdCom recommend Brodalumab approval with restrictions and oral Relistor was approved.

Maris said they expected positive outcomes on today's catalysts and these products are already in... More

Valeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTOR

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration has approved RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Valeant expects to commence sales of RELISTOR Tablets in the U.S. in the third quarter of 2016.

"Opioid-induced constipation represents a long-lasting and potentially debilitating side effect of opioid... More